Answers are grounded in this paper and cite their sources.
SOLTI-PROMETEO evaluated the hypothesis that combining T-VEC, an oncolytic virus, with atezo, could improve outcomes for pts with residual disease (RD) following standard NAC. Here, we report the survival outcomes of this trial.
No takes yet. Share an insight, caveat, or question.
Pascual et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: